IDL Biotech has started the work on mapping the US market.
Read more here
CEO Anders Hultman and CFO Ellen Dittberner present the company’s Q4’25 results – February 26, 2026 Q4 Interview: Redeye talks with CEO Anders Hultman
A strategy update with IDL Diagnostics was held on November 27th at Redeye, where CEO Anders Hultman and the management team presented recent achievements, spotlighted key initiatives, and discussed future opportunities looking toward 2026 and beyond. After their...
Redeye interview with Anders Hultman CEO, commenting on the Interim Report Q3 2025 IDL Diagnostics (Q3 Interview): Redeye talks with CEO Anders Hultman IDL Diagnostics: CEO Anders Hultman and CFO Ellen Dittberner present the company’s Q3’25 results – November...
